CPRX
Price
$19.70
Change
-$0.08 (-0.40%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
2.42B
42 days until earnings call
LGND
Price
$169.12
Change
-$1.53 (-0.90%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
3.33B
42 days until earnings call
Interact to see
Advertisement

CPRX vs LGND

Header iconCPRX vs LGND Comparison
Open Charts CPRX vs LGNDBanner chart's image
Catalyst Pharmaceuticals
Price$19.70
Change-$0.08 (-0.40%)
Volume$26.5K
Capitalization2.42B
Ligand Pharmaceuticals
Price$169.12
Change-$1.53 (-0.90%)
Volume$1.13K
Capitalization3.33B
CPRX vs LGND Comparison Chart in %
Loading...
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CPRX vs. LGND commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPRX is a Hold and LGND is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (CPRX: $19.78 vs. LGND: $170.65)
Brand notoriety: CPRX and LGND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CPRX: 81% vs. LGND: 52%
Market capitalization -- CPRX: $2.42B vs. LGND: $3.33B
CPRX [@Biotechnology] is valued at $2.42B. LGND’s [@Biotechnology] market capitalization is $3.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPRX’s FA Score shows that 1 FA rating(s) are green whileLGND’s FA Score has 0 green FA rating(s).

  • CPRX’s FA Score: 1 green, 4 red.
  • LGND’s FA Score: 0 green, 5 red.
According to our system of comparison, CPRX is a better buy in the long-term than LGND.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPRX’s TA Score shows that 3 TA indicator(s) are bullish while LGND’s TA Score has 3 bullish TA indicator(s).

  • CPRX’s TA Score: 3 bullish, 2 bearish.
  • LGND’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CPRX is a better buy in the short-term than LGND.

Price Growth

CPRX (@Biotechnology) experienced а -1.44% price change this week, while LGND (@Biotechnology) price change was +2.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

CPRX is expected to report earnings on Nov 05, 2025.

LGND is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LGND($3.33B) has a higher market cap than CPRX($2.42B). LGND has higher P/E ratio than CPRX: LGND (46.19) vs CPRX (11.99). LGND YTD gains are higher at: 59.263 vs. CPRX (-5.223). CPRX has higher annual earnings (EBITDA): 281M vs. LGND (-45.94M). CPRX has more cash in the bank: 653M vs. LGND (255M). CPRX has less debt than LGND: CPRX (2.99M) vs LGND (5.74M). CPRX has higher revenues than LGND: CPRX (558M) vs LGND (188M).
CPRXLGNDCPRX / LGND
Capitalization2.42B3.33B73%
EBITDA281M-45.94M-612%
Gain YTD-5.22359.263-9%
P/E Ratio11.9946.1926%
Revenue558M188M297%
Total Cash653M255M256%
Total Debt2.99M5.74M52%
FUNDAMENTALS RATINGS
CPRX vs LGND: Fundamental Ratings
CPRX
LGND
OUTLOOK RATING
1..100
5964
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
2739
SMR RATING
1..100
3495
PRICE GROWTH RATING
1..100
8039
P/E GROWTH RATING
1..100
9890
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPRX's Valuation (49) in the Pharmaceuticals Other industry is in the same range as LGND (73) in the Biotechnology industry. This means that CPRX’s stock grew similarly to LGND’s over the last 12 months.

CPRX's Profit vs Risk Rating (27) in the Pharmaceuticals Other industry is in the same range as LGND (39) in the Biotechnology industry. This means that CPRX’s stock grew similarly to LGND’s over the last 12 months.

CPRX's SMR Rating (34) in the Pharmaceuticals Other industry is somewhat better than the same rating for LGND (95) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than LGND’s over the last 12 months.

LGND's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for CPRX (80) in the Pharmaceuticals Other industry. This means that LGND’s stock grew somewhat faster than CPRX’s over the last 12 months.

LGND's P/E Growth Rating (90) in the Biotechnology industry is in the same range as CPRX (98) in the Pharmaceuticals Other industry. This means that LGND’s stock grew similarly to CPRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CPRXLGND
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
65%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 20 days ago
80%
Bullish Trend 14 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
68%
Bearish Trend 10 days ago
73%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
66%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SQBIX15.12-0.01
-0.07%
X-Square Balanced Fund, LLC Instl
GGCPX16.03-0.04
-0.25%
Goldman Sachs International T/M Eq P
JHTAX20.36-0.07
-0.34%
JPMorgan Hedged Equity 3 A
JANEX149.05-0.64
-0.43%
Janus Henderson Enterprise D
TRMNX23.81-0.15
-0.63%
T. Rowe Price Mid-Cap Index

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with SANA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
-1.35%
SANA - CPRX
49%
Loosely correlated
+0.31%
VIR - CPRX
47%
Loosely correlated
-1.90%
LGND - CPRX
46%
Loosely correlated
-0.07%
SYRE - CPRX
43%
Loosely correlated
+4.77%
CRNX - CPRX
42%
Loosely correlated
+6.35%
More

LGND and

Correlation & Price change

A.I.dvisor indicates that over the last year, LGND has been loosely correlated with AGIO. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if LGND jumps, then AGIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LGND
1D Price
Change %
LGND100%
-0.07%
AGIO - LGND
49%
Loosely correlated
-0.84%
CRSP - LGND
47%
Loosely correlated
-2.16%
SYRE - LGND
47%
Loosely correlated
+4.77%
ACLX - LGND
45%
Loosely correlated
+1.19%
OCUL - LGND
44%
Loosely correlated
+0.41%
More